News

Conference Coverage

First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up

01/12/2026

Stephanie Holland

Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...

Updated results from the phase 3...

01/12/2026

Oncology

Conference Coverage

First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up

01/12/2026

Stephanie Holland

Updated results from the phase 3...

01/12/2026

Oncology

FDA Approval

FDA Approves Y-90 Resin Microspheres for Patients With Unresectable Hepatocellular Carcinoma

07/08/2025

Stephanie Holland

Based on interim results from the DOORwaY90 trial, the FDA has approved Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Based on interim results from...

07/08/2025

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma

07/03/2025

Allison Casey

According to the TALENTACE trial, the addition of atezolizumab and bevacizumab to on-demand transarterial chemoembolization improved the TACE–progression-free survival for treatment-naïve patients with unresectable hepatocellular carcinoma...

According to the TALENTACE...

07/03/2025

Oncology

Conference Coverage

Atezolizumab Plus Bevacizumab Added to On-Demand TACE Improved Survival Outcomes for Patients With Unresectable Hepatocellular Carcinoma

07/03/2025

Allison Casey

According to the TALENTACE...

07/03/2025

Oncology

News

First-Line Anlotinib Plus Penpulimab for Patients With Unresectable Hepatocellular Carcinoma

05/28/2025

Stephanie Holland

According to results from the phase 3 APOLLO trial, first-line anlotinib plus penpulimab significantly improved outcomes compared to anlotinib plus sorafenib among patients with unresectable hepatocellular carcinoma.

According to results from the...

05/28/2025

Oncology

News

Addition of Tiragolumab Shows Promise for Locally Advanced, Unresectable Hepatocellular Carcinoma

02/04/2025

Stephanie Holland

According to results from the phase 1b/2 MORPHEUS-Liver trial, the addition of tiragolumab to atezolizumab plus bevacizumab demonstrated promise among patients with previously untreated locally advanced or unresectable hepatocellular...

According to results from the...

02/04/2025

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Added to TACE Improves Progression-Free Survival for Unresectable Hepatocellular Carcinoma

01/27/2025

Allison Casey

According to a phase 2 study, the addition of camrelizumab and apatinib to transarterial chemoembolization improved the progression-free survival among patients with unresectable hepatocellular carcinoma eligible for embolization.

According to a phase 2 study,...

01/27/2025

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

News

Bevacizumab-Erlotinib Switch Maintenance Improved Progression-Free Survival Among Patients With Advanced Biliary Tract Cancers

08/26/2024

Stephanie Holland

According to results from a phase 2/3 study, bevacizumab-erlotinib switch maintenance improved progression-free survival among patients with chemotherapy-responsive advanced biliary tract cancers.

According to results from a...

08/26/2024

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology